Scienture Holdings, Inc. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Scienture Holdings (market cap ~$10.2M) reported Q3 2026 revenue of $1.25M, up 265% sequentially from $344K in Q2 and 113% YoY from $590K in Q3 2025. REZENOPY (naloxone nasal spray) launched in August 2026 and generated ~$925K in Q3 net product revenue; Arbli (losartan suspension) contributed ~$330K. The company achieved Q3 gross profit of $1.02M (81.3% margin) and narrowed 9-month net loss to $12.2M from $13.4M YoY. Cash position improved to $7.8M (including $3M restricted cash) from $6.7M at year-end 2025. Management expects breakeven operating income and profitability in 2027 based on current sales trajectory.
Why this rating
High-growth commercial inflection (265% sequential, 113% YoY) on micro-cap; two FDA products now generating meaningful revenue materially changes trajectory. Loss narrowing + path to 2027 profitability credible. Relative to $10.2M market cap, $1.25M quarterly revenue is substantial, though execution risk remains material.
Tradability signal
NO TRADE
No trade: positive news with only -1.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=592). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.46 ▲ 1.03% | at our read · unknown $2.44 | +10 min · unknown $2.44 ▲ 0.00% | +30 min · unknown $2.37 ▼ 2.67% | +1 hr · unknown $2.33 ▼ 4.52% | +4 hrs · unknown $2.13 ▼ 12.73% |
The stock had already moved -1.02% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.